NCT05186818Phase 3Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Study sponsor: Cytokinetics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-11-10Actual
Enrollment · participants282Actual
Source updated2026-03-03Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET). After: Measure: Change From Baseline in pVO2 at Week 24.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview